Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 96,699
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12570709 | Self-assembling peptide amphiphiles displaying a transforming growth factor beta 1 (TGF-ß1) mimetic epitope | 🖼🧊📄§ | 2026-03-10 | 2042-07-28 | 0 | 31 |
| 12570759 | Polypeptides | 🖼🧊📄§ | 2026-03-10 | 2039-12-17 | 0 | 31 |
| 12570753 | Combination therapies with anti CD40 antibodies | 🖼🧊📄§ | 2026-03-10 | 2043-12-13 | 0 | 31 |
| 12569570 | Compositions and methods for targeted RNA delivery | 🖼🧊📄§ | 2026-03-10 | 2044-01-23 | 0 | 31 |
| 12569561 | Double stranded oligonucleotide construct comprising androgen receptor specific sequence, and composition for preventing hair loss and promoting hair growth comprising same | 🖼🧊📄§ | 2026-03-10 | 2039-11-18 | 0 | 31 |
| 12569431 | Immunostimulatory method | 🖼🧊📄§ | 2026-03-10 | 2043-10-10 | 0 | 31 |
| 12569432 | Aerosol generator | 🖼🧊📄§ | 2026-03-10 | 2040-05-12 | 0 | 31 |
| 12569450 | Nanoparticles for medical and diagnostic applications | 🖼🧊📄§ | 2026-03-10 | 2040-11-09 | 0 | 31 |
| 12569481 | Methods of treatment for gastrointestinal motility disorders | 🖼🧊📄§ | 2026-03-10 | 2041-06-11 | 0 | 31 |
| 12569487 | Treatment of hidradenitis with jak inhibitors | 🖼🧊📄§ | 2026-03-10 | 2040-09-08 | 0 | 31 |
| 12569506 | Methods of treating osteonecrosis with LLP2A-bisphosphonate compounds | 🖼🧊📄§ | 2026-03-10 | 2040-08-18 | 0 | 31 |
| 12568993 | Shelf-stable nitrogenous organic acid compositions | 🖼🧊📄§ | 2026-03-10 | 2038-10-18 | 0 | 31 |
| 12573519 | Materials and processes for generating radioisotopes | 🖼🧊📄§ | 2026-03-10 | 2045-05-21 | 0 | 31 |
| 12573050 | Systems and methods for platform agnostic whole body image segmentation | 🖼🧊📄§ | 2026-03-10 | 2044-01-31 | 0 | 31 |
| 12570961 | Methods and compositions for T-cell coculture potency assays and use with cell therapy products | 🖼🧊📄§ | 2026-03-10 | 2042-03-25 | 0 | 31 |
| 12570973 | Compositions and methods for inhibiting intermediate filament tetramerization | 🖼🧊📄§ | 2026-03-10 | 2039-10-08 | 0 | 31 |
| 12570978 | Methods and compositions for macrophage polarization | 🖼🧊📄§ | 2026-03-10 | 2042-11-04 | 0 | 31 |
| 12571000 | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof | 🖼🧊📄§ | 2026-03-10 | 2044-01-19 | 0 | 31 |
| 12571002 | Gene therapies for lysosomal disorders | 🖼🧊📄§ | 2026-03-10 | 2041-07-07 | 0 | 31 |
| 12571052 | Immunomodulatory RNA | 🖼🧊📄§ | 2026-03-10 | 2042-05-19 | 0 | 31 |
| 12570621 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | 🖼🧊📄§ | 2026-03-10 | 2043-07-27 | 0 | 31 |
| 12570627 | Pharmaceutical composition in which production of impurities is suppressed | 🖼🧊📄§ | 2026-03-10 | 2041-05-13 | 0 | 31 |
| 12570638 | Fused imidazole derivatives as AHR antagonists | 🖼🧊📄§ | 2026-03-10 | 2041-05-19 | 0 | 31 |
| 12570632 | Indole derivatives and uses thereof for treating a cancer | 🖼🧊📄§ | 2026-03-10 | 2041-07-06 | 0 | 31 |
| 12570642 | GLP-IR modulating compounds | 🖼🧊📄§ | 2026-03-10 | 2043-10-27 | 0 | 31 |
| 12570655 | Cysteine covalent modifiers of AKT1 and uses thereof | 🖼🧊📄§ | 2026-03-10 | 2045-05-30 | 0 | 31 |
| 12570663 | Crystal forms of an anti-sars CoV-2 agent | 🖼🧊📄§ | 2026-03-10 | 2043-10-05 | 0 | 31 |
| 12570664 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 🖼🧊📄§ | 2026-03-10 | 2045-04-17 | 0 | 31 |
| 12570672 | Macrocyclic compounds and methods of use | 🖼🧊📄§ | 2026-03-10 | 2044-03-25 | 0 | 31 |
| 12570696 | Tumor-specific polypeptide sequence and use thereof | 🖼🧊📄§ | 2026-03-10 | 2039-11-07 | 0 | 31 |
| 12570699 | Capsid-modified, rAAV3 vector compositions and methods of use in gene therapy of human liver cancer | 🖼🧊📄§ | 2026-03-10 | 2040-12-23 | 0 | 31 |
| 12570700 | SARS-CoV-2 spike receptor binding domain and compositions and methods thereof | 🖼🧊📄§ | 2026-03-10 | 2041-03-25 | 0 | 31 |
| 12570701 | Ferritin nanoparticle displaying an HIV trimer | 🖼🧊📄§ | 2026-03-10 | 2039-06-05 | 0 | 31 |
| 12570705 | Modified ligand-gated ion channels and methods of use | 🖼🧊📄§ | 2026-03-10 | 2041-08-09 | 0 | 31 |
| 12570715 | T cell receptors and methods of use thereof | 🖼🧊📄§ | 2026-03-10 | 2040-07-29 | 0 | 31 |
| 12570712 | Cyclin A1 specific T cell receptors and uses thereof | 🖼🧊📄§ | 2026-03-10 | 2039-02-12 | 0 | 31 |
| 12570714 | Siglec-based chimeric polypeptides and uses thereof | 🖼🧊📄§ | 2026-03-10 | 2040-04-16 | 0 | 31 |
| 12570710 | Targeting LILRB4 with CAR-T or CAR-NK cells in the treatment of cancer | 🖼🧊📄§ | 2026-03-10 | 2038-11-06 | 0 | 31 |
| 12570719 | Chimeric antigen receptor comprising anti c-met antibody or antigen binding fragment thereof, and use thereof | 🖼🧊📄§ | 2026-03-10 | 2040-09-25 | 0 | 31 |
| 12570716 | Anti-dinitrophenol chimeric antigen receptors | 🖼🧊📄§ | 2026-03-10 | 2041-02-02 | 0 | 31 |
| 12570717 | Anti-B-cell maturation antigen chimeric antigen receptors with human domains | 🖼🧊📄§ | 2026-03-10 | 2043-11-30 | 0 | 31 |
| 12570724 | Preparation method for biosynthesis of human body structural material | 🖼🧊📄§ | 2026-03-10 | 2044-12-30 | 0 | 31 |
| 12570723 | Recombinant humanized collagen type III alpha-1, and expression vector and use thereof | 🖼🧊📄§ | 2026-03-10 | 2043-12-26 | 0 | 31 |
| 12570731 | Methods for treating cancer with an anti-apo B100 antibody | 🖼🧊📄§ | 2026-03-10 | 2040-11-12 | 0 | 31 |
| 12570730 | Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors | 🖼🧊📄§ | 2026-03-10 | 2040-07-17 | 0 | 31 |
| 12570734 | C-terminal anti-sclerostin antibody variants | 🖼🧊📄§ | 2026-03-10 | 2043-11-30 | 0 | 31 |
| 12570738 | Multi-specific antibody with binding specificity for human IL-13 and IL-17 | 🖼🧊📄§ | 2026-03-10 | 2040-12-18 | 0 | 31 |
| 12570739 | Compositions and methods for improving health through modulating CALHM2 | 🖼🧊📄§ | 2026-03-10 | 2041-10-15 | 0 | 31 |
| 12570743 | BCMA-targeting engineered immune cell and use thereof | 🖼🧊📄§ | 2026-03-10 | 2040-05-06 | 0 | 31 |
| 12570742 | Anti-SIRPα monoclonal antibodies and uses thereof | 🖼🧊📄§ | 2026-03-10 | 2041-11-18 | 0 | 31 |